Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Vet Comp Oncol ; 15(2): 470-480, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-27174040

RESUMO

Pamidronate is a bisphosphonate drug widely utilized in veterinary oncologic practice for the palliation of malignant osteolysis. Pamidronate has not been previously reported to cause tissue injury upon extravasation in dogs. The medical records of 11 client-owned dogs undergoing palliative treatment for primary bone tumors with known or suspected pamidronate extravasation reactions were reviewed. The majority of adverse events were low grade in nature, however in some cases, the reactions were severe and led to euthanasia in one instance. Time to complete resolution of lesions ranged from within several days to greater than one and a half months. Aside from the dog that was euthanized, no long-term sequelae of extravasation were identified. Treatments employed to address the reactions varied widely. Pamidronate extravasation reaction appears to be an uncommon, but potentially serious complication of intravenous administration.


Assuntos
Vasos Sanguíneos/efeitos dos fármacos , Conservadores da Densidade Óssea/efeitos adversos , Neoplasias Ósseas/veterinária , Difosfonatos/efeitos adversos , Doenças do Cão/induzido quimicamente , Osteólise/veterinária , Animais , Conservadores da Densidade Óssea/uso terapêutico , Neoplasias Ósseas/complicações , Difosfonatos/uso terapêutico , Doenças do Cão/tratamento farmacológico , Cães , Feminino , Masculino , Osteólise/tratamento farmacológico , Osteólise/etiologia , Pamidronato , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...